Skip to content
Screener

Arrowhead Research ARWR Net debt / EBITDA

Net debt / EBITDA at other companies

ALN
Alnylam PharmaceuticalsALNY
-1.4×—
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
-0.1×—
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
-116.1×—
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-1.6×—

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.28B+445%
Enterprise value$12.2B+446%
P/S19.7×+15.8×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Calculated from Arrowhead Research’s reported figures.

net debt/ebitda=-0.3×

Based on the most recent quarter.

The source filing: Arrowhead Research’s 10-Q, filed February 5, 2026. Open the filing →

Filed
Feb 5, 2026, 4:06 PM EST
Fiscal quarter
Q1 FY2026
Calendar quarter
Q4 2025
Accession
0000879407-26-000034

FAQ

What is Arrowhead Research's net debt / EBITDA?
Arrowhead Research (ARWR) reported net debt / EBITDA of -0.3× in Q4 2025.
What does net debt / EBITDA mean?
Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.

Ask your AI about Arrowhead Research's net debt / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude